Triple
T17093447
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | NewLink Genetics |
E414780
|
entity |
| Predicate | developed |
P73
|
FINISHED |
| Object |
navoximod
Navoximod is an investigational small-molecule inhibitor of the immune checkpoint enzyme IDO1, studied as a cancer immunotherapy agent.
|
E1249865
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69d886cfc8e88190b05ba466edd35591 |
elicitation | completed |
| NER | batch_69e3dbfb89348190942984037bd3bd2e |
ner | completed |
| NED1 | batch_6a012eec0d5c8190806e756aae848ba2 |
ned_source_triple | completed |
| NED2 | batch_6a012ffb67d4819099ec8d668cb590c9 |
ned_description | completed |
| NEDg | batch_6a012f7f8b148190914b0d7cfb2d5c5c |
nedg | completed |
Created at: April 10, 2026, 5:35 a.m.